H. Heinrichs

发表

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

M. Zaaroor, U. Bogdahn, K. Schlingensiepen, 2010, Neuro-oncology.

Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).

M. Wolzt, H. Eichler, S. Eichinger, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

U. Tebbe, A. Jessel, K. Neuhaus, 1994, Circulation.

Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

M. Lamy, L. Thijs, B. Eisele, 1998, Intensive care medicine.

Preliminary results of a phase I/II study in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma using systemic i.v. administration of AP 12009

K. Schlingensiepen, T. Seufferlein, H. Oettle, 2008 .

HLA non-A,B,C class I genes: Their structure and expression

H. Orr, H. Heinrichs, 1990, Immunologic research.

Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.

A. Enk, A. Hauschild, C. Garbe, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.

H. Rupprecht, W. Terres, J. Meyer, 1996, European heart journal.

Expression of major histocompatibility antigens on human thymocytes studied using monoclonal antibodies

P. Wernet, A. Ziegler, H. Heinrichs, 2005, Immunogenetics.

K562 cells express human major histocompatibility antigens

P. Wernet, A. Ziegler, B. Uchánska‐Ziegler, 2004, Immunogenetics.

Effect of recombinant human erythropoietin after allogeneic bone marrow transplantation

W. Ebell, M. Freund, M. Stoll, 1993, Annals of Hematology.

Comparison of Three Routes of Administration of Recombinant Human Erythropoietin Expressed in C-127 Mouse Cells

H. Heinrichs, T. Brune, G. Reiner, 1992 .

High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial

S. Opal, P. Singer, R. Bone, 2001 .

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

S. Opal, P. Singer, R. Bone, 2001, JAMA.

Antithrombin III in patients with severe sepsis: a pharmacokinetic study

J. Decruyenaere, L. Thijs, S. Knaub, 2000, Intensive Care Medicine.

Antithrombin III in patients with severe sepsis

L. Thijs, B. Eisele, U. Delvos, 1998, Intensive Care Medicine.

Recombinant Human Erythropoietin After Bone Marrow Transplantation — A Placebo Controlled Trial

F. Mandelli, S. Burdach, M. Boogaerts, 1996 .

Extraembryonic expression of the human MHC class I gene HLA-G in transgenic mice. Evidence for a positive regulatory region located 1 kilobase 5' to the start site of transcription.

M. Athanasiou, H. Orr, L. Duvick, 1993, Journal of immunology.

Genetic regulation of the antibody response to H-2Db alloantigens in mice. IV. Antigens that activate helper T cells for IgG, coded for by the non-H-2 genome.

P. Wernet, D. Wernet, H. Heinrichs, 1982, Journal of immunology.

Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma.

K. Schlingensiepen, T. Seufferlein, H. Oettle, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase Iib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma

U. Bogdahn, K. Schlingensiepen, A. Mahapatra, 2008 .

Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints.

U. Bogdahn, K. Schlingensiepen, A. Mahapatra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A controlled trial of recombinant human erythropoietin after bone marrow transplantation.

F. Mandelli, S. Burdach, J. Reiffers, 1994, Blood.

Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: Results of a phase Iib study

U. Bogdahn, K. Schlingensiepen, A. Mahapatra, 2008 .

The role of cardiovascular research and clinical training in health care reform.

E. Antman, M. Laks, C. Schmid, 1994, Circulation.

Results of a phase IIb study in recurrent or refractory glioblastoma patients with the TGF-beta-2 inhibitor AP 12009

U. Bogdahn, K. Schlingensiepen, A. Mahapatra, 2007 .